HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis.

AbstractBACKGROUND:
Rheumatic heart disease (RHD) accounts for the highest number of deaths from valvular heart disease globally. Yet, rheumatic aortic stenosis (AS) was excluded from landmark studies investigating the safety and efficacy of transcatheter aortic valve implantation (TAVI). We aimed to describe the clinical and anatomical characteristics of patients with rheumatic AS undergoing TAVI, and to compare procedural and clinical outcomes with patients undergoing TAVI for degenerative AS.
METHODS:
In a prospective TAVI registry, patients with rheumatic AS were identified based on International Classification of Diseases version 10 codes and/or a documented history of acute rheumatic fever and/or the World Heart Federation criteria for echocardiographic diagnosis of RHD, and were propensity score-matched in a 1:4 ratio to patients with degenerative AS.
RESULTS:
Among 2329 patients undergoing TAVI, 105 (4.5%) had rheumatic AS. Compared with patients with degenerative AS, patients with rheumatic AS were more commonly female, older, had higher surgical risk and more commonly suffered from multivalvular heart disease. In the unmatched cohort, both technical success (85.7% vs 85.9%, p=0.887) and 1-year cardiovascular mortality (10.0% vs 8.6%; HR 1.16, 95% CI 0.61 to 2.18, p=0.656) were comparable between patients with rheumatic and degenerative AS. In contrast, patients with rheumatic AS had lower rates of 30-day and 1-year cardiovascular mortality compared with matched patients with degenerative AS (1.9% vs 8.9%, adjusted HR (HRadj) 0.18, 95% CI 0.04 to 0.80, p=0.024; and 10.0% vs 20.3%, HRadj 0.44, 95% CI 0.24 to 0.84, p=0.012, respectively).
CONCLUSION:
TAVI may be a safe and effective treatment strategy for selected elderly patients with rheumatic AS.
TRIAL REGISTRATION NUMBER:
NCT01368250.
AuthorsTaishi Okuno, Daijiro Tomii, Eric Buffle, Jonas Lanz, Christoph Ryffel, Caglayan Demirel, Suliman Hashemi, Daniel Hagemeyer, Athanasios Papadis, Dik Heg, Fabien Praz, Stefan Stortecky, Stephan Windecker, Thomas Pilgrim
JournalHeart (British Cardiac Society) (Heart) Vol. 108 Issue 15 Pg. 1225-1233 (07 13 2022) ISSN: 1468-201X [Electronic] England
PMID35351823 (Publication Type: Clinical Study, Journal Article)
Copyright© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Topics
  • Aged
  • Aortic Valve Stenosis (surgery)
  • Female
  • Humans
  • Male
  • Propensity Score
  • Prospective Studies
  • Risk Factors
  • Transcatheter Aortic Valve Replacement (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: